| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2bb22307c154aa30f8b6c0eb8005492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb7ef983baff507dddec389e2535dcfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c435c3f91b1cf6ac9cb8350751c18ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dd388a5130b0bdede0fdfc6c2af6ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916075766043ce900399a4c2eee9f054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a999962df16076fa61addb384b52b052 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7452 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate |
2007-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e88674ca9c88c60074284a59792aeb20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6c3f1430e89cd4c2ee52d0cea85d476
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49decf44389f53f6673d8115f40ff1e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d07f1014cf640aae671ff12e1c29c77d |
| publicationDate |
2008-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007106893-A3 |
| titleOfInvention |
Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| abstract |
The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. |
| priorityDate |
2006-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |